Latest Ipo News

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Maas Group Holdings prepares to release its FY25 audited results on August 21, followed by the release of over 660,000 shares from voluntary escrow, marking a key milestone since its 2020 IPO.

Orezone Gold Corporation reports solid Q2-2025 results from its Bomboré Gold Mine, maintaining production guidance and progressing major expansion projects on schedule and budget.

Orezone Gold Corporation reported solid Q2 2025 results with robust earnings and production, while progressing its hard rock expansion projects on schedule. The company’s recent ASX listing and board-approved stage 2 expansion signal a transformative growth phase.

Orezone Gold Corporation reported a robust first half of 2025 with net earnings of $36.7 million and advanced its Bomboré mine expansion, while completing a significant ASX IPO.

HomeCo Daily Needs REIT has delivered on its FY25 financial guidance, showcasing strong operational metrics and a robust development pipeline that sets the stage for growth in FY26.

Orezone Gold Corporation has successfully completed its initial public offering on the ASX, raising A$75 million to fund expansion at its Bomboré Mine. The company's CHESS Depository Interests started trading under the ticker 'ORE' on August 8, 2025.

Kelly Partners Group Holdings posted a robust 24.5% revenue increase to $134.6 million in FY25, driven by strategic international expansions and acquisitions. The firm’s underlying profit after tax also rose 13%, underscoring its growing footprint across Australia, the US, and Ireland.

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Lithium Energy Limited has made significant strides in its Capricorn Gold-Copper Belt and White Plains Lithium Brine projects, secured government funding, and received a major tranche payment from the Solaroz sale, while shelving its graphite IPO plans amid market challenges.